Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Casdatifan shows durable response linked to HIF-2α biology in kidney cancer.

Nature·2026
Same author

Long-term follow-up from the OMNIVORE trial: response-adaptive nivolumab and ipilimumab in advanced renal cell carcinoma.

Journal for immunotherapy of cancer·2026
Same author

Simulation and empirical evaluation of biologically-informed neural network performance.

Machine learning with applications·2026
Same author

Evaluating agentic AI for biological discovery in autonomous and copilot settings.

bioRxiv : the preprint server for biology·2026
Same author

Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib.

Cancer·2026
Same author

Evaluating the immediate impacts of the repeal of the Northern Territory minimum unit price on off-premises alcohol pricing: Findings from an observational study of online alcohol retailers.

Addiction (Abingdon, England)·2026
Same journal

Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Metabolic Modulation in Cancer Care: The Potential Role of Glucagon-Like Peptide-1 Receptor Agonists.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same journal

First-Line Disitamab Vedotin, Tislelizumab, and S-1 in HER2-Overexpressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Single-Arm, Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
See all related articles

Related Experiment Video

Updated: May 9, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With

Rana R McKay1, Wanling Xie2, Archana Ajmera1

  • 1University of California San Diego, La Jolla, CA.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|May 7, 2026
PubMed
Summary
This summary is machine-generated.

Combining olaparib with radium-223 significantly improved radiographic progression-free survival (rPFS) in men with metastatic castration-resistant prostate cancer (mCRPC). This combination therapy demonstrated manageable toxicity and warrants further investigation for DNA damage-targeted strategies.

More Related Videos

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
03:07

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Published on: August 19, 2025

Related Experiment Videos

Last Updated: May 9, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
03:07

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Published on: August 19, 2025

Area of Science:

  • Oncology
  • Radiopharmaceutical Therapy
  • Medical Oncology

Background:

  • Metastatic castration-resistant prostate cancer (mCRPC) is a significant cause of mortality.
  • Radium-223, an alpha-emitting radiopharmaceutical, improves survival in mCRPC patients.
  • Preclinical studies suggest synergy between poly(ADP-ribose) polymerase (PARP) inhibitors and radiation therapy.

Purpose of the Study:

  • To evaluate the efficacy and safety of combining olaparib with radium-223 versus radium-223 alone in men with mCRPC.
  • To assess the impact of this combination on radiographic progression-free survival (rPFS) and skeletal-related events.

Main Methods:

  • A randomized phase II trial involving 120 men with mCRPC and at least two bone metastases (BM).
  • Patients were assigned to receive either olaparib plus radium-223 or radium-223 alone.
  • The primary endpoint was investigator-assessed rPFS; crossover was permitted at progression.

Main Results:

  • The combination of olaparib and radium-223 significantly improved median rPFS (8.9 vs. 4.7 months; HR, 0.50; P=.0042).
  • Benefits were most pronounced in patients without prior docetaxel or with ≤20 BM.
  • Increased hematologic toxicities (lymphopenia, anemia, thrombocytopenia) were observed with the combination, but the regimen was manageable.

Conclusions:

  • Olaparib plus radium-223 offers a significant improvement in rPFS for mCRPC patients with BM compared to radium-223 alone.
  • The combination therapy, despite increased hematologic toxicity, is manageable.
  • These findings support further investigation of DNA damage-targeted strategies in mCRPC.